Diabetes Prevention Program Reauthorization Act of 2026
- Sponsor
- Rep. De La Cruz, Monica [R-TX-15]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- Aug 13, 2026
Bottom line
This bill ensures continued and increased federal funding for the National Diabetes Prevention Program, a public health initiative aimed at preventing type 2 diabetes.
What it actually does
This bill reauthorizes the National Diabetes Prevention Program (NDPP) by amending the Public Health Service Act to specify exact funding levels for fiscal years 2027 through 2031. It replaces the previous authorization of "such sums as may be necessary" with concrete, increasing annual appropriations, ensuring a stable and growing financial commitment to the program.
Proponents argue
Supporters argue that reauthorizing and increasing funding for the National Diabetes Prevention Program is crucial for public health, as it provides evidence-based interventions to individuals at high risk of developing type 2 diabetes, leading to better health outcomes and potentially reducing long-term healthcare costs associated with diabetes treatment. They emphasize the program's proven effectiveness in helping participants make lifestyle changes that prevent or delay the onset of the disease.
Opponents contend
Critics, if any, might argue against specific funding levels, suggesting that the proposed increases are either insufficient to meet the program's needs or excessive given other budgetary priorities. Some might also question the efficiency or reach of the program, advocating for alternative approaches or more rigorous evaluation of its cost-effectiveness, although direct opposition to diabetes prevention programs is rare.
The bill is exceptionally short and clear, making it very accessible for any reader to understand its core purpose and provisions quickly.
Section 2
Reauthorization and Funding for National Diabetes Prevention Program
This section updates the Public Health Service Act to explicitly reauthorize the National Diabetes Prevention Program (NDPP) for five additional fiscal years, from 2027 to 2031. Instead of open-ended "such sums as may be necessary," it sets specific, increasing annual appropriations, starting at $39.3 million in 2027 and rising to $59.3 million by 2031. This ensures a defined and growing financial commitment to the program.
Supporters argue
Supporters argue that providing specific, increasing funding ensures the stability and growth of a vital public health program. This predictable funding allows for long-term planning, expansion of services to underserved populations, and continued investment in a program proven to reduce healthcare costs by preventing a chronic disease.
Critics contend
No specific opposition is typically raised against the reauthorization of the National Diabetes Prevention Program itself, given its public health benefits. Potential critics might focus on the specific funding levels, arguing for either higher amounts to meet greater demand or lower amounts due to fiscal conservatism, or suggesting that state and local governments should bear more of the cost.
Tradeoffs
The primary tension involves balancing the demonstrated public health benefits and long-term cost savings of diabetes prevention against immediate federal budgetary outlays. While prevention programs can reduce future healthcare expenditures, they require upfront investment, which must be weighed against other federal spending priorities.